546 related articles for article (PubMed ID: 24060760)
1. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
Freedberg DE; Salmasian H; Friedman C; Abrams JA
Am J Gastroenterol; 2013 Nov; 108(11):1794-801. PubMed ID: 24060760
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
[TBL] [Abstract][Full Text] [Related]
4. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.
McDonald EG; Milligan J; Frenette C; Lee TC
JAMA Intern Med; 2015 May; 175(5):784-91. PubMed ID: 25730198
[TBL] [Abstract][Full Text] [Related]
5. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
6. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.
Oshima T; Wu L; Li M; Fukui H; Watari J; Miwa H
J Gastroenterol; 2018 Jan; 53(1):84-94. PubMed ID: 28744822
[TBL] [Abstract][Full Text] [Related]
7. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study.
Park YH; Seong JM; Cho S; Han HW; Kim JY; An SH; Gwak HS
J Gastroenterol; 2019 Dec; 54(12):1052-1060. PubMed ID: 31187275
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings.
Appaneal HJ; Caffrey AR; Beganovic M; Avramovic S; LaPlante KL
Am J Health Syst Pharm; 2019 Apr; 76(9):581-590. PubMed ID: 31361830
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy.
King RN; Lager SL
Pharmacotherapy; 2011 Jul; 31(7):642-8. PubMed ID: 21923450
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
Saruta Y; Watanabe K; Tsuji T; Takahashi Y; Matsuzawa H; Yoshida T; Takahashi S; Shimodaira Y; Matsuhashi T; Iijima K
J Gastroenterol Hepatol; 2023 Jun; 38(6):940-947. PubMed ID: 36882162
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.
Barletta JF; Sclar DA
Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.
Gordon D; Young LR; Reddy S; Bergman C; Young JD
J Hosp Infect; 2016 Feb; 92(2):173-7. PubMed ID: 26616410
[TBL] [Abstract][Full Text] [Related]
13. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection.
Inghammar M; Svanström H; Voldstedlund M; Melbye M; Hviid A; Mølbak K; Pasternak B
Clin Infect Dis; 2021 Jun; 72(12):e1084-e1089. PubMed ID: 33629099
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of recurrent Clostridium difficile infection in out-patients.
Shivashankar R; Khanna S; Kammer PP; Scott Harmsen W; Zinsmeister AR; Baddour LM; Pardi DS
Aliment Pharmacol Ther; 2014 Sep; 40(5):518-22. PubMed ID: 25039269
[TBL] [Abstract][Full Text] [Related]
15. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.
Trifan A; Stanciu C; Girleanu I; Stoica OC; Singeap AM; Maxim R; Chiriac SA; Ciobica A; Boiculese L
World J Gastroenterol; 2017 Sep; 23(35):6500-6515. PubMed ID: 29085200
[TBL] [Abstract][Full Text] [Related]
17. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.
Dial S; Alrasadi K; Manoukian C; Huang A; Menzies D
CMAJ; 2004 Jul; 171(1):33-8. PubMed ID: 15238493
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Risk of Hospital-Acquired Clostridium Difficile Infection With Proton Pump Inhibitor Use: A Meta-Analysis.
Arriola V; Tischendorf J; Musuuza J; Barker A; Rozelle JW; Safdar N
Infect Control Hosp Epidemiol; 2016 Dec; 37(12):1408-1417. PubMed ID: 27677811
[TBL] [Abstract][Full Text] [Related]
19. Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics.
Lewis PO; Lundberg TS; Tharp JL; Runnels CW
Ann Pharmacother; 2017 Oct; 51(10):848-854. PubMed ID: 28821215
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
